Phage displaya powerful technique for immunotherapy: 1. Introduction and potential of therapeutic applications

Human Vaccines and Immunotherapeutics

Volumn 8, Issue 12, 2012, Pages 1817-1828

  Bazan, Justyna ^a   Całkosiñski, Ireneusz ^a   Gamian, Andrzej ^a  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

Antibody libraries; Autoimmune diseases; Immune diagnostics; Neurological disorders; Phage display; Transfusion medicine; Tumor targeting

Indexed keywords

ALEMTUZUMAB; ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN; CARCINOEMBRYONIC ANTIGEN; CORTICOSTEROID; CYSTYLLEUCYLSERYLTYROSYLTYROSYLPROLYLSERYLTYROSYLCYSTEINE; CYSTYLLYSYLGLYCYLGLYCYLARGINYLALANYLLYSYLASPARTYLCYSTEINE; CYSTYLPROLYLISOLEUCYLGLUTAMIDYLASPARTYLARGINYLPROLYLMETHIONYLCYSTEINE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GLUTAMIDYLPHENYLALANYLARGINYLHISTIDINE; GLYCOPROTEIN IIB; GLYCOPROTEIN IIIA; HUMAN PLATELET ANTIBODY 1A; IMMUNOGLOBULIN F(AB')2 FRAGMENT; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN FRAGMENT; ISOLEUCYLALANYLGLYCYLLEUCYLALANYLTHREONYLPROLYLGLYCYLTRYPTOPANYLSERYLHISTIDYLTRYPTOPANYLLEUCYLALANYLLEUCINE; MONOCLONAL ANTIBODY; NICOTINIC RECEPTOR; NONSTEROID ANTIINFLAMMATORY AGENT; PEPTIDE; PRION PROTEIN; RHESUS D ANTIBODY; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; SYNTHETIC PEPTIDE; THROMBOCYTE ANTIBODY; THROMBOCYTE ANTIGEN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; IMMUNOLOGIC FACTOR;

ANTIANGIOGENIC ACTIVITY; ANTIBODY AFFINITY; ANTIBODY COMBINING SITE; ANTIBODY LIBRARY; ANTIBODY PRODUCTION; ANTIGEN ANTIBODY COMPLEX; ANTIGEN BINDING; ANTINEOPLASTIC ACTIVITY; AUTOIMMUNE DISEASE; BACTERIOPHAGE LAMBDA; BINDING AFFINITY; BINDING SITE; BIOMEDICAL TECHNOLOGY ASSESSMENT; BIOMEDICINE; BIOTECHNOLOGY; BLOOD TRANSFUSION; CELL HOMING; CREUTZFELDT JAKOB DISEASE; DISULFIDE BOND; DRUG DETERMINATION; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; ENCAPSULATION; EPITOPE MAPPING; FATAL FAMILIAL INSOMNIA; GENOTYPE; GERSTMANN STRAUSSLER SCHEINKER SYNDROME; HEMAGGLUTINATION TEST; HUMAN; HYBRIDOMA CELL CULTURE; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOGENICITY; IMMUNOMODULATION; IMMUNOTHERAPY; IRIDOCYCLITIS; KURU; LIGAND BINDING; LINKAGE ANALYSIS; MOLECULAR CLONING; MOLECULAR IMAGING; MOLECULAR INTERACTION; MULTIPLE SCLEROSIS; MYASTHENIA GRAVIS; NEONATAL ALLOIMMUNE THROMBOCYTOPENIA; NEUROLOGIC DISEASE; NONHUMAN; PARKINSON DISEASE; PHAGE DISPLAY; PHENOTYPE; PROSTATE CANCER; PROTEIN BINDING; RECEPTOR BINDING; REVIEW; RHEUMATOID ARTHRITIS; SYSTEM ANALYSIS; TRANSFUSION MEDICINE; ANTIBODY LIBRARIES; CELL SURFACE DISPLAY; DRUG DEVELOPMENT; IMMUNE-DIAGNOSTICS; ISOLATION AND PURIFICATION; METHODOLOGY; NEUROLOGICAL DISORDERS; TUMOR TARGETING; PROCEDURES;

ANTIBODY LIBRARIES; AUTOIMMUNE DISEASES; IMMUNE-DIAGNOSTICS; NEUROLOGICAL DISORDERS; PHAGE DISPLAY; TRANSFUSION MEDICINE; TUMOR TARGETING;

CELL SURFACE DISPLAY TECHNIQUES; DRUG DISCOVERY; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOTHERAPY;

EID: 84872226661     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.21703     Document Type: Review

References (167)

1. Smith GP. Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. Science 1985; 228:1315-7; PMID:4001944; http://dx.doi.org/10.1126/science.4001944.
2. Kaplan G, Gershoni JM. A general insert label for peptide display on chimeric filamentous bacteriophages. Anal Biochem 2012; 420:68-72; PMID:21945353; http://dx.doi.org/10.1016/j.ab.2011.08.050.
3. Hoffmann S, Funke SA, Wiesehan K, Moedder S, Glück JM, Feuerstein S, et al. Competitively selected protein ligands pay their increase in specificity by a decrease in affinity. Mol Biosyst 2010; 6:126-33; PMID:20024074; http://dx.doi.org/10.1039/b910945e.
4. Zhang J, Li H, Wang X, Qi H, Miao X, Zhang T, et al. Phage-derived fully human antibody scFv fragment directed against human vascular endothelial growth factor receptor 2 blocked its interaction with VEGF. Biotechnol Prog 2012; 28:981-9; PMID:22581629; http://dx.doi.org/10.1002/btpr.1559.
5. Schüller C, Wiebe JC, Pegel A, Kramer K, Skerra A, Hock B. A system for repertoire cloning and phage display of murine and leporid antibody fragments. J AOAC Int 2010; 93:66-79; PMID:20334167.
6. Cho W, Fowler JD, Furst EM. Targeted binding of the M13 bacteriophage to thiamethoxam organic crystals. Langmuir 2012; 28:6013-20; PMID:22404231; http://dx.doi.org/10.1021/la300522g.
7. Hess GT, Cragnolini JJ, Popp MW, Allen MA, Dougan SK, Spooner E, et al. M13 bacteriophage display framework that allows sortase-mediated modification of surface-accessible phage proteins. Bioconjug Chem 2012; 23:1478-87; PMID:22759232; http://dx.doi.org/10.1021/bc300130z.
8. Fagerlund A, Myrset AH, Kulseth MA. Construction and characterization of a 9-mer phage display pVIII-library with regulated peptide density. Appl Microbiol Biotechnol 2008; 80:925-36; PMID:18716770; http://dx.doi.org/10.1007/ s00253-008-1630-z.
9. Li L, Arumuganathan K, Gill KS, Song Y. Flow sorting and microcloning of maize chromosome 1. Hereditas 2004; 141:55-60; PMID:15383072; http://dx.doi.org/10.1111/j.1601-5223.2004.01847.x.
10. Garbe D, Thiel IV, Mootz HD. Protein trans-splicing on an M13 bacteriophage: towards directed evolution of a semisynthetic split intein by phage display. J Pept Sci 2010; 16:575-81; PMID:20862725; http://dx.doi.org/10. 1002/psc.1243.
11. Oh MY, Joo HY, Hur BU, Jeong YH, Cha SH. Enhancing phage display of antibody fragments using gIII-amber suppression. Gene 2007; 386:81-9; PMID:17088027; http://dx.doi.org/10.1016/j.gene.2006.08.009.
12. Rondot S, Koch J, Breitling F, Dübel S. A helper phage to improve single-chain antibody presentation in phage display. Nat Biotechnol 2001; 19:75-8; PMID:11135557; http://dx.doi.org/10.1038/83567.
13. Sidhu SS, Weiss GA, Wells JA. High copy display of large proteins on phage for functional selections. J Mol Biol 2000; 296:487-95; PMID:10669603; http://dx.doi.org/10.1006/jmbi.1999.3465.
14. Løset GA, Bogen B, Sandlie I. Expanding the versatility of phage display I: efficient display of peptide-tags on protein VII of the filamentous phage. PLoS One 2011; 6:e14702; PMID:21390217; http://dx.doi.org/10.1371/ journal.pone.0014702.
15. Løset GA, Roos N, Bogen B, Sandlie I. Expanding the versatility of phage display II: improved affinity selection of folded domains on protein VII and IX of the filamentous phage. PLoS One 2011; 6:e17433; PMID:21390283; http://dx.doi.org/10.1371/journal.pone.0017433.
16. Fuh G, Pisabarro MT, Li Y, Quan C, Lasky LA, Sidhu SS. Analysis of PDZ domain-ligand interactions using carboxyl-terminal phage display. J Biol Chem 2000; 275:21486-91; PMID:10887205.
17. Speck J, Arndt KM, Müller KM. Efficient phage display of intracellularly folded proteins mediated by the TAT pathway. Protein Eng Des Sel 2011; 24:473-84; PMID:21289038; http://dx.doi.org/10.1093/protein/gzr001.
18. Krumpe LR, Atkinson AJ, Smythers GW, Kandel A, Schumacher KM, McMahon JB, et al. T7 lytic phage-displayed peptide libraries exhibit less sequence bias than M13 filamentous phage-displayed peptide libraries. Proteomics 2006; 6:4210-22; PMID:16819727; http://dx.doi.org/10.1002/pmic.200500606.
19. Kang HT, Bang WK, Yu YG. Identification and characterization of a novel angiostatin-binding protein by the display cloning method. J Biochem Mol Biol 2004; 37:159-66; PMID:15469691; http://dx.doi.org/10.5483/BMBRep.2004.37.2.159.
20. Ishi K, Sugawara F. A facile method to screen inhibitors of protein-protein interactions including MDM2-p53 displayed on T7 phage. Biochem Pharmacol 2008; 75:1743-50; PMID:18384755; http://dx.doi.org/10.1016/j.bcp.2008. 01.020.
21. Wu J, Tu C, Yu X, Zhang M, Zhang N, Zhao M, et al. Bacteriophage T4 nanoparticle capsid surface SOC and HOC bipartite display with enhanced classical swine fever virus immunogenicity: a powerful immunological approach. J Virol Methods 2007; 139:50-60; PMID:17081627; http://dx.doi.org/10.1016/j. jviromet.2006.09.017.
22. Cicchini C, Ansuini H, Amicone L, Alonzi T, Nicosia A, Cortese R, et al. Searching for DNA-protein interactions by lambda phage display. J Mol Biol 2002; 322:697-706; PMID:12270707; http://dx.doi.org/10.1016/S0022-2836(02)00851-3.
23. Gao J, Wang Y, Liu Z, Wang Z. Phage display and its application in vaccine design. Ann Microbiol 2010; 60:13-9; http://dx.doi.org/10.1007/s13213- 009-0014-7.
24. Hamers-Casterman C, Atarhouch T, Muyldermans S, Robinson G, Hamers C, Songa EB, et al. Naturally occurring antibodies devoid of light chains. Nature 1993; 363:446-8; PMID:8502296; http://dx.doi.org/10.1038/363446a0.
25. Mahgoub IO. Expression and Characterization of a Functional Single-Chain Variable Fragment (scFv) Protein Recognizing MCF7 Breast Cancer Cells in E. coli Cytoplasm. Biochem Genet 2012; 50:625-41; PMID:22552770; http://dx.doi.org/10. 1007/s10528-012-9506-4.
26. Sonoda H, Kumada Y, Katsuda T, Yamaji H. Effects of cytoplasmic and periplasmic chaperones on secretory production of single-chain Fv antibody in Escherichia coli. J Biosci Bioeng 2011; 111:465-70; PMID:21324738; http://dx.doi.org/10.1016/j.jbiosc.2010.12.015.
27. Carlsson F, Trilling M, Perez F, Ohlin M. A dimerized single-chain variable fragment system for the assessment of neutralizing activity of phage display-selected antibody fragments specific for cytomegalovirus. J Immunol Methods 2012; 376:69-78; PMID:22154743; http://dx.doi.org/10.1016/j.jim.2011.11. 010.
28. Wen K, Nölke G, Schillberg S, Wang Z, Zhang S, Wu C, et al. Improved fluoroquinolone detection in ELISA through engineering of a broad-specific single-chain variable fragment binding simultaneously to 20 fluoroquinolones. Anal Bioanal Chem 2012; 403:2771-83; PMID:22549819; http://dx.doi.org/10.1007/ s00216-012-6062-z.
29. Hughes DL, Stafford P, Hamaia SW, Harmer J, Schoolmeester A, Deckmyn H, et al. Platelet integrin alpha2 I-domain specific antibodies produced via domain specific DNA vaccination combined with variable gene phage display. Thromb Haemost 2005; 94:1318-26; PMID:16411412.
30. Shimazaki K, Lepin EJ, Wei B, Nagy AK, Coulam CP, Mareninov S, et al. Diabodies targeting epithelial membrane protein 2 reduce tumorigenicity of human endometrial cancer cell lines. Clin Cancer Res 2008; 14:7367-77; PMID:19010852; http://dx.doi.org/10.1158/1078-0432.CCR-08-1016.
31. Kawasaki T, Onodera K, Kamijo S. Identification of novel short peptide inhibitors of soluble 37/48 kDa oligomers of amyloid â42. Biosci Biotechnol Biochem 2011; 75:1496-501; PMID:21821948; http://dx.doi.org/10.1271/ bbb.110198.
32. Heskamp S, van Laarhoven HW, Molkenboer-Kuenen JD, Bouwman WH, van der Graaf WT, Oyen WJ, et al. Optimization of IGF-1R SPECT/CT imaging using (111)In-labeled F(ab')(2) and Fab fragments of the monoclonal antibody R1507. Mol Pharm 2012; In press; PMID:22747077; http://dx.doi.org/10.1021/mp300232n.
33. Markiv A, Beatson R, Burchell J, Durvasula RV, Kang AS. Expression of recombinant multi-coloured fluorescent antibodies in gor -/trxB- E. coli cytoplasm. BMC Biotechnol 2011; 11:117; PMID:22129156; http://dx.doi.org/10. 1186/1472-6750-11-117.
34. Tang YM, Ning BT, Cao J, Shen HQ, Qian BQ. Construction and expression of single-chain antibody derived from a new clone of monoclonal antibody against human CD14 in CHO cells. Immunopharmacol Immunotoxicol 2007; 29:375-86; PMID:18075851; http://dx.doi.org/10.1080/08923970701619927.
35. Neri D, Momo M, Prospero T, Winter G. High-affinity antigen binding by chelating recombinant antibodies (CRAbs). J Mol Biol 1995; 246:367-73; PMID:7533215; http://dx.doi.org/10.1006/jmbi.1994.0091.
36. Wright MJ, Deonarain MP. Phage display of chelating recombinant antibody libraries. Mol Immunol 2007; 44:2860-9; PMID:17353051; http://dx.doi.org/10. 1016/j.molimm.2007.01.026.
37. Lomonosova AV, Laman AG, Fursova KK, Shepelyakovskaya AO, Vertiev YV, Brovko FA, et al. Generation of scFv phages specific to Staphylococcus enterotoxin C1 by panning on related antigens. MAbs 2011; 3:513-6; PMID:22123058; http://dx.doi.org/10.4161/mabs.3.6.18089.
38. Liu B, Huang L, Sihlbom C, Burlingame A, Marks JD. Towards proteome-wide production of monoclonal antibody by phage display. J Mol Biol 2002; 315:1063-73; PMID:11827476; http://dx.doi.org/10.1006/jmbi.2001.5276.
39. Garet E, Cabado AG, Vieites JM, González-Fernández A. Rapid isolation of single-chain antibodies by phage display technology directed against one of the most potent marine toxins: Palytoxin. Toxicon 2010; 55:1519-26; PMID:20223256; http://dx.doi.org/10.1016/j.toxicon.2010.03.005.
40. Chang C, Takayanagi A, Yoshida T, Shimizu N. Screening of scFv-displaying phages recognizing distinct extracellular domains of EGF receptor by target-guided proximity labeling method. J Immunol Methods 2011; 372:127-36; PMID:21782821; http://dx.doi.org/10.1016/j.jim.2011.07.003.
41. Noronha EJ, Wang X, Ferrone S. Isolation of human tumor-associated cell surface antigen-binding scFvs. Methods Mol Biol 2002; 178:227-33; PMID:11968492.
42. Chakravarthy B, Ménard M, Brown L, Atkinson T, Whitfield J. Identification of protein kinase C inhibitory activity associated with a polypeptide isolated from a phage display system with homology to PCM-1, the pericentriolar material-1 protein. Biochem Biophys Res Commun 2012; 424:147-51; PMID:22732405; http://dx.doi.org/10.1016/j.bbrc.2012.06.093.
43. Hallborn J, Carlsson R. Automated screening procedure for high-throughput generation of antibody fragments. Biotechniques 2002; (Suppl): 30-7; PMID:12514927.
44. Rubenwolf S, Niewöhner J, Meyer E, Petit-Frère C, Rudert F, Hoffmann PR, et al. Functional proteomics using chromophore-assisted laser inactivation. Proteomics 2002; 2:241-6; PMID:11921439; http://dx.doi.org/10. 1002/1615-9861(200203)2:3〈241::AID-PROT241\〉3.0.CO;2-7.
45. Konthur Z. High-throughput applications of phage display in proteomic analyses. Targets 2003; 2:261-70; http://dx.doi.org/10.1016/S1477-3627(03)02383- 3.
46. Almagro JC, Raghunathan G, Beil E, Janecki DJ, Chen Q, Dinh T, et al. Characterization of a high-affinity human antibody with a disulfide bridge in the third complementarity-determining region of the heavy chain. J Mol Recognit 2012; 25:125-35; PMID:22407976; http://dx.doi.org/10.1002/jmr.1168.
47. Hughes-Jones NC, Gorick BD, Bye JM, Finnern R, Scott ML, Voak D, et al. Characterization of human blood group scFv antibodies derived from a V gene phage-display library. Br J Haematol 1994; 88:180-6; PMID:7803241; http://dx.doi.org/10.1111/j.1365-2141.1994.tb04994.x.
48. Watkins NA, Armour KL, Smethurst PA, Metcalfe P, Scott ML, Hughes DL, et al. Rapid phenotyping of HPA-1a using either diabody-based hemagglutination or recombinant IgG1-based assays. Transfusion 1999; 39:781-9; PMID:10413288; http://dx.doi.org/10.1046/j.1537-2995.1999.39070781.x.
49. Siegel D, Loftu JC, McMillan R. Characterization of an ITP patient-derived anti-alpha(2b)beta(3) monoclonal antibody that inhibits platelet aggregation. Blood 2003; 102:87A-A.
50. Dahan R, Tabul M, Chou YK, Meza-Romero R, Andrew S, Ferro AJ, et al. TCR-like antibodies distinguish conformational and functional differences in two- versus four-domain auto reactive MHC class II-peptide complexes. Eur J Immunol 2011; 41:1465-79; PMID:21469129; http://dx.doi.org/10.1002/eji. 201041241.
51. Dogan I, Dorgham K, Chang HC, Parizot C, Lemaître F, Ferradini L, et al. Phage-displayed libraries of peptide/major histocompatibility complexes. Eur J Immunol 2004; 34:598-607; PMID:14768065; http://dx.doi.org/10.1002/eji. 200324721.
52. Finlay WJ, Bloom L, Cunningham O. Optimized generation of high-affinity, high-specificity single-chain Fv antibodies from multiantigen immunized chickens. Methods Mol Biol 2011; 681:383-401; PMID:20978977; http://dx.doi.org/10.1007/978-1-60761-913-0-21.
53. Hofer T, Tangkeangsirisin W, Kennedy MG, Mage RG, Raiker SJ, Venkatesh K, et al. Chimeric rabbit/human Fab and IgG specific for members of the Nogo-66 receptor family selected for species cross-reactivity with an improved phage display vector. J Immunol Methods 2007; 318:75-87; PMID:17140598; http://dx.doi.org/10.1016/j.jim.2006.10.007.
54. Charlton K, Harris WJ, Porter AJ. The isolation of super-sensitive anti-hapten antibodies from combinatorial antibody libraries derived from sheep. Biosens Bioelectron 2001; 16:639-46; PMID:11679239; http://dx.doi.org/10.1016/ S0956-5663(01)00192-0.
55. Chahboun S, Hust M, Liu Y, Pelat T, Miethe S, Helmsing S, et al. Isolation of a nanomolar scFv inhibiting the endopeptidase activity of botulinum toxin A, by single-round panning of an immune phage-displayed library of macaque origin. BMC Biotechnol 2011; 11:113; PMID:22111995; http://dx.doi.org/ 10.1186/1472-6750-11-113.
56. Yang XD, Jia XC, Corvalan JR, Wang P, Davis CG, Jakobovits A. Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy. Cancer Res 1999; 59:1236-43; PMID:10096554.
57. Tabares-da Rosa S, Rossotti M, Carleiza C, Carrión F, Pritsch O, Ahn KC, et al. Competitive selection from single domain antibody libraries allows isolation of high-affinity antihapten antibodies that are not favored in the llama immune response. Anal Chem 2011; 83:7213-20; PMID:21827167; http://dx.doi.org/10.1021/ac201824z.
58. Fu YY, Li ZG, Yang YW, Deng W, Duan W, Miao Q, et al. Isolation of single chain variable fragments against six esters of pyrethrins by subtractive phage display. Biosci Biotechnol Biochem 2009; 73:1541-9; PMID:19584536; http://dx.doi.org/10.1271/bbb.90043.
59. Moon SA, Ki MK, Lee S, Hong ML, Kim M, Kim S, et al. Antibodies against non-immunizing antigens derived from a large immune scFv library. Mol Cells 2011; 31:509-13; PMID:21499952; http://dx.doi.org/10.1007/s10059-011-2268-8.
60. Vaughan TJ, Williams AJ, Pritchard K, Osbourn JK, Pope AR, Earnshaw JC, et al. Human antibodies with sub-nanomolar affinities isolated from a large non-immunized phage display library. Nat Biotechnol 1996; 14:309-14; PMID:9630891; http://dx.doi.org/10.1038/nbt0396-309.
61. Griffiths AD, Malmqvist M, Marks JD, Bye JM, Embleton MJ, McCafferty J, et al. Human anti-self antibodies with high specificity from phage display libraries. EMBO J 1993; 12:725-34; PMID:7679990.
62. Babel I, Barderas R, Peláez-García A, Casal JI. Antibodies on demand: a fast method for the production of human scFvs with minimal amounts of antigen. BMC Biotechnol 2011; 11:61; PMID:21635725; http://dx.doi.org/10. 1186/1472-6750-11-61.
63. Stoyanova V, Aleksandrov R, Lukarska M, Duhalov D, Atanasov V, Petrova S. Recognition of Vipera ammodytes meridionalis neurotoxin vipoxin and its components using phage-displayed scFv and polyclonal antivenom sera. Toxicon 2012; 60:802-9; PMID:22750218; http://dx.doi.org/10.1016/j.toxicon.2012.06.003.
64. Azzazy HM, Highsmith WE Jr. Phage display technology: clinical applications and recent innovations. Clin Biochem 2002; 35:425-45; PMID:12413604; http://dx.doi.org/10.1016/S0009-9120(02)00343-0.
65. Knappik A, Ge L, Honegger A, Pack P, Fischer M, Wellnhofer G, et al. Fully synthetic human combinatorial antibody libraries (HuCAL) based on modular consensus frameworks and CDRs randomized with trinucleotides. J Mol Biol 2000; 296:57-86; PMID:10656818; http://dx.doi.org/10.1006/jmbi.1999.3444.
66. Krebs B, Rauchenberger R, Reiffert S, Rothe C, Tesar M, Thomassen E, et al. High-throughput generation and engineering of recombinant human antibodies. J Immunol Methods 2001; 254:67-84; PMID:11406154; http://dx.doi.org/10.1016/ S0022-1759(01)00398-2.
67. Hughes-Jones NC, Bye JM, Gorick BD, Marks JD, Ouwehand WH. Synthesis of Rh Fv phage-antibodies using VH and VL germline genes. Br J Haematol 1999; 105:811-6; PMID:10354152; http://dx.doi.org/10.1046/j.1365-2141.1999.01412.x.
68. van den Beucken T, van Neer N, Sablon E, Desmet J, Celis L, Hoogenboom HR, et al. Building novel binding ligands to B7.1 and B7.2 based on human antibody single variable light chain domains. J Mol Biol 2001; 310:591-601; PMID:11439026; http://dx.doi.org/10.1006/jmbi.2001.4703.
69. Chen W, Zhu Z, Feng Y, Dimitrov DS. A large human domain antibody library combining heavy and light chain CDR3 diversity. Mol Immunol 2010; 47:912-21; PMID:19883941; http://dx.doi.org/10.1016/j.molimm.2009.09.039.
70. Markovic-Plese S, Hemmer B, Zhao Y, Simon R, Pinilla C, Martin R. High level of cross-reactivity in influenza virus hemagglutinin-specific CD4+ T-cell response: implications for the initiation of autoimmune response in multiple sclerosis. J Neuroimmunol 2005; 169:31-8; PMID:16150497; http://dx.doi.org/10. 1016/j.jneuroim.2005.07.014.
71. Chan CE, Chan AH, Lim AP, Hanson BJ. Comparison of the efficiency of antibody selection from semisynthetic scFv and non-immune Fab phage display libraries against protein targets for rapid development of diagnostic immunoassays. J Immunol Methods 2011; 373:79-88; PMID:21856306; http://dx.doi.org/10.1016/j.jim.2011.08.005.
72. Marks JD, Ouwehand WH, Bye JM, Finnern R, Gorick BD, Voak D, et al. Human antibody fragments specific for human blood group antigens from a phage display library. Biotechnology (N Y) 1993; 11:1145-9; PMID:7764095; http://dx.doi.org/10.1038/nbt1093-1145.
73. Huie MA, Cheung MC, Muench MO, Becerril B, Kan YW, Marks JD. Antibodies to human fetal erythroid cells from a nonimmune phage antibody library. Proc Natl Acad Sci U S A 2001; 98:2682-7; PMID:11226299; http://dx.doi.org/10.1073/ pnas.051631798.
74. Fitting J, Killian D, Junghanss C, Willenbrock S, Murua Escobar H, Lange S, et al. Generation of recombinant antibody fragments that target canine dendritic cells by phage display technology. Vet Comp Oncol 2011; 9:183-95; PMID:21848621; http://dx.doi.org/10.1111/j.1476-5829.2010.00246.x.
75. Kreitman RJ, Tallman MS, Robak T, Coutre S, Wilson WH, Stetler-Stevenson M, et al. Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia. J Clin Oncol 2012; 30:1822-8; PMID:22355053; http://dx.doi.org/10.1200/JCO.2011.38.1756.
76. O'Nuallain B, Allen A, Ataman D, Weiss DT, Solomon A, Wall JS. Phage display and peptide mapping of an immunoglobulin light chain fibril-related conformational epitope. Biochemistry 2007; 46:13049-58; PMID:17944486; http://dx.doi.org/10.1021/bi701255m.
77. Maeda M, Ito Y, Hatanaka T, Hashiguchi S, Torikai M, Nakashima T, et al. Regulation of T cell response by blocking the ICOS signal with the B7RP-1-specific small antibody fragment isolated from human antibody phage library. MAbs 2009; 1:453-61; PMID:20065650; http://dx.doi.org/10.4161/mabs.1.5. 9633.
78. Barth S, Huhn M, Matthey B, Tawadros S, Schnell R, Schinköthe T, et al. Ki-4(scFv)-ETA', a new recombinant anti-CD30 immunotoxin with highly specific cytotoxic activity against disseminated Hodgkin tumors in SCID mice. Blood 2000; 95:3909-14; PMID:10845927.
79. Löffler A, Kufer P, Lutterbüse R, Zettl F, Daniel PT, Schwenkenbecher JM, et al. A recombinant bispecific single-chain antibody, CD19 x CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes. Blood 2000; 95:2098-103; PMID:10706880.
80. Chu XX, Hou M, Peng J, Zhu YY, Ji XB, Wang L, et al. Effects of IgG and its F(ab')2 fragments of some patients with idiopathic thrombocytopenic purpura on platelet aggregation. Eur J Haematol 2006; 76:153-9; PMID:16405437; http://dx.doi.org/10.1111/j.1600-0609.2005.00557.x.
81. Tsuruta LR, Tomioka Y, Hishinuma T, Kato Y, Itoh K, Suzuki T, et al. Characterization of 11-dehydro-thromboxane B2 recombinant antibody obtained by phage display technology. Prostaglandins Leukot Essent Fatty Acids 2003; 68:273-84; PMID:12628223; http://dx.doi.org/10.1016/S0952-3278(03)00006-1.
82. Suggett S, Kirchhofer D, Hass P, Lipari T, Moran P, Nagel M, et al. Use of phage display for the generation of human antibodies that neutralize factor IXa function. Blood Coagul Fibrinolysis 2000; 11:27-42; PMID:10691097.
83. Gevorkian G, Manoutcharian K, Almagro JC, Govezensky T, Dominguez V. Identification of autoimmune thrombocytopenic purpura-related epitopes using phage-display peptide library. Clin Immunol Immunopathol 1998; 86:305-9; PMID:9557164; http://dx.doi.org/10.1006/clin.1997.4502.
84. Luken BM, Kaijen PH, Turenhout EA, Kremer Hovinga JA, van Mourik JA, Fijnheer R, et al. Multiple B-cell clones producing antibodies directed to the spacer and disintegrin/thrombospondin type-1 repeat 1 (TSP1) of ADAMTS13 in a patient with acquired thrombotic thrombocytopenic purpura. J Thromb Haemost 2006; 4:2355-64; PMID:16898953; http://dx.doi.org/10.1111/j.1538-7836.2006. 02164.x.
85. Kim Y, Caberoy NB, Alvarado G, Davis JL, Feuer WJ, Li W. Identification of Hnrph3 as an autoantigen for acute anterior uveitis. Clin Immunol 2011; 138:60-6; PMID:20943442; http://dx.doi.org/10.1016/j.clim.2010.09.008.
86. Zhang Y, Davis JL, Li W. Identification of tribbles homolog 2 as an autoantigen in autoimmune uveitis by phage display. Mol Immunol 2005; 42:1275-81; PMID:15950723; http://dx.doi.org/10.1016/j.molimm.2004.11.020.
87. Finnern R, Pedrollo E, Fisch I, Wieslander J, Marks JD, Lockwood CM, et al. Human autoimmune antiproteinase 3 scFv from a phage display library. Clin Exp Immunol 1997; 107:269-81; PMID:9030863; http://dx.doi.org/10.1111/j.1365- 2249.1997.254-ce1127.x.
88. Latrofa F, Pichurin P, Guo J, Rapoport B, McLachlan SM. Thyroglobulin-thyroperoxidase autoantibodies are polyreactive, not bispecific: analysis using human monoclonal autoantibodies. J Clin Endocrinol Metab 2003; 88:371-8; PMID:12519879; http://dx.doi.org/10.1210/jc.2002-021073.
89. Farilla L, Tiberti C, Luzzago A, Yu L, Eisenbarth GS, Cortese R, et al. Application of phage display peptide library to autoimmune diabetes: identification of IA-2/ICA512bdc dominant autoantigenic epitopes. Eur J Immunol 2002; 32:1420-7; PMID:11981830; http://dx.doi. org/10.1002/1521-4141(200205)32: 5〈1420::AIDIMMU1420\〉3.0.CO;2-B.
90. Payne AS, Ishii K, Kacir S, Lin C, Li H, Hanakawa Y, et al. Genetic and functional characterization of human pemphigus vulgaris monoclonal autoantibodies isolated by phage display. J Clin Invest 2005; 115:888-99; PMID:15841178.
91. Ishii K, Lin C, Siegel DL, Stanley JR. Isolation of pathogenic monoclonal anti-desmoglein 1 human antibodies by phage display of pemphigus foliaceus autoantibodies. J Invest Dermatol 2008; 128:939-48; PMID:18007588; http://dx.doi.org/10.1038/sj.jid.5701132.
92. Ikuno N, Scealy M, Davies JM, Whittingham SF, Omagari K, Mackay IR, et al. A comparative study of antibody expressions in primary biliary cirrhosis and autoimmune cholangitis using phage display. Hepatology 2001; 34:478-86; PMID:11526532; http://dx.doi.org/10.1053/jhep.2001.27013.
93. Jensen-Jarolim E, Neumann C, Oberhuber G, Gscheidlinger R, Neuchrist C, Reinisch W, et al. Anti-Galectin-3 IgG autoantibodies in patients with Crohn's disease characterized by means of phage display peptide libraries. J Clin Immunol 2001; 21:348-56; PMID:11720007; http://dx.doi.org/10.1023/A: 1012240719801.
94. Sblattero D, Not T, Marzari R, Bradbury A. Phage Antibody Library From Celiac Disease Patient. J Pediatr Gastroenterol Nutr 1999; 28:568; http://dx.doi.org/10.1097/00005176-199905000-00117.
95. Graus YF, de Baets MH, van Breda Vriesman PJ, Burton DR. Anti-acetylcholine receptor Fab fragments isolated from thymus-derived phage display libraries from myasthenia gravis patients reflect predominant specificities in serum and block the action of pathogenic serum antibodies. Immunol Lett 1997; 57:59-62; PMID:9232426; http://dx.doi.org/10.1016/S0165- 2478(97)00046-1.
96. Venkatesh N, Im SH, Balass M, Fuchs S, Katchalski-Katzir E. Prevention of passively transferred experimental autoimmune myasthenia gravis by a phage library-derived cyclic peptide. Proc Natl Acad Sci U S A 2000; 97:761-6; PMID:10639153; http://dx.doi.org/10.1073/pnas.97.2.761.
97. Osbourn JK, Jermutus L, Duncan A. Current methods for the generation of human antibodies for the treatment of autoimmune diseases. Drug Discov Today 2003; 8:845-51; PMID:12963321; http://dx.doi.org/10.1016/S1359-6446(03)02803-4.
98. Rau R. Adalimumab (a fully human anti-tumour necrosis factor alpha monoclonal antibody) in the treatment of active rheumatoid arthritis: the initial results of five trials. Ann Rheum Dis 2002; 61(Suppl 2):ii70-3; PMID:12379628.
99. Klotz L, Meuth SG, Wiendl H. Immune mechanisms of new therapeutic strategies in multiple sclerosis-A focus on alemtuzumab. Clin Immunol 2012; 142:25-30; PMID:21550857; http://dx.doi.org/10.1016/j.clim.2011.04.006.
100. Coles AJ, Cox A, Le Page E, Jones J, Trip SA, Deans J, et al. The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy. J Neurol 2006; 253:98-108; PMID:16044212; http://dx.doi.org/ 10.1007/s00415-005-0934-5.
101. Rajpal A, Turi TG. Intracellular stability of anti-caspase-3 intrabodies determines efficacy in retargeting the antigen. J Biol Chem 2001; 276:33139-46; PMID:11425853; http://dx.doi.org/10.1074/jbc.M101332200.
102. Tsai MK, Lin RH, Hsu BR, Lee PH. Lipofection of pcDNA3-CTLA4-Ig into B cells promotes allogeneic hyporesponsiveness. Transplant Proc 2003; 35:548-9; PMID:12591526; http://dx.doi.org/10.1016/S0041-1345(02)03768-5.
103. Jazi MH, Dabaghian M, Tebianian M, Gharagozlou MJ, Ebrahimi SM. In vivo electroporation enhances immunogenicity and protection against influenza A virus challenge of an M2e-HSP70c DNA vaccine. Virus Res 2012; 167:219-25; PMID:22609252; http://dx.doi.org/10.1016/j.virusres.2012.05.002.
104. Langedijk JP, Olijhoek T, Schut D, Autar R, Meloen RH. New transport peptides broaden the horizon of applications for peptidic pharmaceuticals. Mol Divers 2004; 8:101-11; PMID:15209161; http://dx.doi.org/10.1023/B:MODI. 0000025653.26130.ce.
105. Thanongsaksrikul J, Chaicumpa W. Botulinum neurotoxins and botulism: a novel therapeutic approach. Toxins (Basel) 2011; 3:469-88; PMID:22069720; http://dx.doi.org/10.3390/toxins3050469.
106. Skrlj N, Serbec VC, Dolinar M. Single-chain Fv antibody fragments retain binding properties of the monoclonal antibody raised against peptide P1 of the human prion protein. Appl Biochem Biotechnol 2010; 160:1808-21; PMID:19597999; http://dx.doi.org/10.1007/s12010-009-8699-4.
107. Emadi S, Liu R, Yuan B, Schulz P, McAllister C, Lyubchenko Y, et al. Inhibiting aggregation of alpha-synuclein with human single chain antibody fragments. Biochemistry 2004; 43:2871-8; PMID:15005622; http://dx.doi.org/10. 1021/bi036281f.
108. Zhou C, Emadi S, Sierks MR, Messer A. A human single-chain Fv intrabody blocks aberrant cellular effects of overexpressed alpha-synuclein. Mol Ther 2004; 10:1023-31; PMID:15564134; http://dx.doi.org/10.1016/j.ymthe.2004.08.019.
109. Gearhart DA, Toole PF, Warren Beach J. Identification of brain proteins that interact with 2-methylnorharman. An analog of the parkinsonian-inducing toxin, MPP+. Neurosci Res 2002; 44:255-65; PMID:12413654; http://dx.doi.org/10. 1016/S0168-0102(02)00133-5.
110. Lecerf JM, Shirley TL, Zhu Q, Kazantsev A, Amersdorfer P, Housman DE, et al. Human singlechain Fv intrabodies counteract in situ huntingtin aggregation in cellular models of Huntington's disease. Proc Natl Acad Sci U S A 2001; 98:4764-9; PMID:11296304; http://dx.doi.org/10.1073/pnas.071058398.
111. Kenan DJ, Strittmatter WJ, Burke JR. Phage display screening for peptides that inhibit polyglutamine aggregation. Methods Enzymol 2006; 413:253-73; PMID:17046401; http://dx.doi.org/10.1016/S0076-6879(06)13014-1.
112. Solomon B, Frenkel D. Generation and brain delivery of anti-aggregating antibodies against beta-amyloid plaques using phage display technology. J Neural Transm Suppl 2002; (62):321-5; PMID:12456075.
113. Solomon B. Active immunization against Alzheimer's beta-amyloid peptide using phage display technology. Vaccine 2007; 25:3053-6; PMID:17287054; http://dx.doi.org/10.1016/j.vaccine.2007.01.069.
114. Frenkel D, Katz O, Solomon B. Immunization against Alzheimer's beta -amyloid plaques via EFRH phage administration. Proc Natl Acad Sci U S A 2000; 97:11455-9; PMID:11027345; http://dx.doi.org/10.1073/pnas.97.21.11455.
115. Chen YH, Chang M, Davidson BL. Molecular signatures of disease brain endothelia provide new sites for CNS-directed enzyme therapy. Nat Med 2009; 15:1215-8; PMID:19749771; http://dx.doi.org/10.1038/nm.2025.
116. Xia H, Anderson B, Mao Q, Davidson BL. Recombinant human adenovirus: targeting to the human transferrin receptor improves gene transfer to brain microcapillary endothelium. J Virol 2000; 74:11359-66; PMID:11070036; http://dx.doi.org/10.1128/JVI.74.23.11359-11366.2000.
117. Lee HJ, Engelhardt B, Lesley J, Bickel U, Pardridge WM. Targeting rat anti-mouse transferrin receptor monoclonal antibodies through blood-brain barrier in mouse. J Pharmacol Exp Ther 2000; 292:1048-52; PMID:10688622.
118. Essler M, Ruoslahti E. Molecular specialization of breast vasculature: a breast-homing phage-displayed peptide binds to aminopeptidase P in breast vasculature. Proc Natl Acad Sci U S A 2002; 99:2252-7; PMID:11854520; http://dx.doi.org/10.1073/pnas.251687998.
119. Arap W, Haedicke W, Bernasconi M, Kain R, Rajotte D, Krajewski S, et al. Targeting the prostate for destruction through a vascular address. Proc Natl Acad Sci U S A 2002; 99:1527-31; PMID:11830668; http://dx.doi.org/10.1073/pnas. 241655998.
120. Lu S, Xu X, Zhao W, Wu W, Yuan H, Shen H, et al. Targeting of embryonic stem cells by peptide-conjugated quantum dots. PLoS One 2010; 5:e12075; PMID:20711469; http://dx.doi.org/10.1371/journal.pone.0012075.
121. Gothard D, Tare RS, Mitchell PD, Dawson JI, Oreffo RO. In search of the skeletal stem cell: isolation and separation strategies at the macro/micro scale for skeletal regeneration. Lab Chip 2011; 11:1206-20; PMID:21350777; http://dx.doi.org/10.1039/c0lc00575d.
122. Arap W, Kolonin MG, Trepel M, Lahdenranta J, Cardó-Vila M, Giordano RJ, et al. Steps toward mapping the human vasculature by phage display. Nat Med 2002; 8:121-7; PMID:11821895; http://dx.doi.org/10.1038/nm0202-121.
123. White SJ, Nicklin SA, Sawamura T, Baker AH. Identification of peptides that target the endothelial cell-specific LOX-1 receptor. Hypertension 2001; 37:449-55; PMID:11230317; http://dx.doi.org/10.1161/01.HYP.37.2.449.
124. Gerlag DM, Borges E, Tak PP, Ellerby HM, Bredesen DE, Pasqualini R, et al. Suppression of murine collagen-induced arthritis by targeted apoptosis of synovial neovasculature. Arthritis Res 2001; 3:357-61; PMID:11714389; http://dx.doi.org/10.1186/ar327.
125. Kolonin MG, Saha PK, Chan L, Pasqualini R, Arap W. Reversal of obesity by targeted ablation of adipose tissue. Nat Med 2004; 10:625-32; PMID:15133506; http://dx.doi.org/10.1038/nm1048.
126. Boger DL, Goldberg J, Silletti S, Kessler T, Cheresh DA. Identification of a novel class of small-molecule antiangiogenic agents through the screening of combinatorial libraries which function by inhibiting the binding and localization of proteinase MMP2 to integrin alpha(V)beta(3). J Am Chem Soc 2001; 123:1280-8; PMID:11456699; http://dx.doi.org/10.1021/ja003579+.
127. Cooke SP, Boxer GM, Lawrence L, Pedley RB, Spencer DI, Begent RH, et al. A strategy for antitumor vascular therapy by targeting the vascular endothelial growth factor: receptor complex. Cancer Res 2001; 61:3653-9; PMID:11325835.
128. Haubner R, Wester HJ, Burkhart F, Senekowitsch-Schmidtke R, Weber W, Goodman SL, et al. Glycosylated RGD-containing peptides: tracer for tumor targeting and angiogenesis imaging with improved biokinetics. J Nucl Med 2001; 42:326-36; PMID:11216533.
129. Chester KA, Begent RH, Robson L, Keep P, Pedley RB, Boden JA, et al. Phage libraries for generation of clinically useful antibodies. Lancet 1994; 343:455-6; PMID:7905958; http://dx.doi.org/10.1016/S0140-6736(94)92695-6.
130. Kelly KA, Jones DA. Isolation of a colon tumor specific binding peptide using phage display selection. Neoplasia 2003; 5:437-44; PMID:14670181.
131. Pierce MC, Javier DJ, Richards-Kortum R. Optical contrast agents and imaging systems for detection and diagnosis of cancer. Int J Cancer 2008; 123:1979-90; PMID:18712733; http://dx.doi.org/10.1002/ijc.23858.
132. Edwards WB, Xu B, Akers W, Cheney PP, Liang K, Rogers BE, et al. Agonist-antagonist dilemma in molecular imaging: evaluation of a monomolecular multimodal imaging agent for the somatostatin receptor. Bioconjug Chem 2008; 19:192-200; PMID:18020401; http://dx.doi.org/10.1021/bc700291m.
133. Adachi S, Yoshimura T, Matsuoka T, Okada K, Yasuda T, Kamei K. [Appearance of skin and nail toxicity in patients with breast cancer who underwent trastuzumab-containing chemotherapy]. Gan To Kagaku Ryoho 2011; 38:1453-6; PMID:21918340.
134. Reubi JC. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev 2003; 24:389-427; PMID:12920149; http://dx.doi.org/10.1210/ er.2002-0007.
135. McGuire MJ, Samli KN, Chang YC, Brown KC. Novel ligands for cancer diagnosis: selection of peptide ligands for identification and isolation of B-cell lymphomas. Exp Hematol 2006; 34:443-52; PMID:16569591; http://dx.doi.org/10.1016/j.exphem.2005.12.013.
136. Robinson P, Stuber D, Deryckère F, Tedbury P, Lagrange M, Orfanoudakis G. Identification using phage display of peptides promoting targeting and internalization into HPV-transformed cell lines. J Mol Recognit 2005; 18:175-82; PMID:15384175; http://dx.doi.org/10.1002/jmr.723.
137. Rasmussen UB, Schreiber V, Schultz H, Mischler F, Schughart K. Tumor cell-targeting by phage-displayed peptides. Cancer Gene Ther 2002; 9:606-12; PMID:12082461; http://dx.doi.org/10.1038/sj.cgt.7700476.
138. Liang S, Lin T, Ding J, Pan Y, Dang D, Guo C, et al. Screening and identification of vascular-endothelial-cell-specific binding peptide in gastric cancer. J Mol Med (Berl) 2006; 84:764-73; PMID:16763842; http://dx.doi.org/10. 1007/s00109-006-0064-2.
139. Askoxylakis V, Zitzmann S, Mier W, Graham K, Krämer S, von Wegner F, et al. Preclinical evaluation of the breast cancer cell-binding peptide, p160. Clin Cancer Res 2005; 11:6705-12; PMID:16166451; http://dx.doi.org/10.1158/1078- 0432.CCR-05-0432.
140. Chang DK, Lin CT, Wu CH, Wu HC. A novel peptide enhances therapeutic efficacy of liposomal anti-cancer drugs in mice models of human lung cancer. PLoS One 2009; 4:e4171; PMID:19137069; http://dx.doi.org/10.1371/journal.pone. 0004171.
141. Wu C, Lo SL, Boulaire J, Hong ML, Beh HM, Leung DS, et al. A peptide-based carrier for intracellular delivery of proteins into malignant glial cells in vitro. J Control Release 2008; 130:140-5; PMID:18632177; http://dx.doi.org/10.1016/j.jconrel.2008.05.015.
142. Du B, Qian M, Zhou Z, Wang P, Wang L, Zhang X, et al. In vitro panning of a targeting peptide to hepatocarcinoma from a phage display peptide library. Biochem Biophys Res Commun 2006; 342:956-62; PMID:16598852; http://dx.doi.org/ 10.1016/j.bbrc.2006.02.050.
143. Zitzmann S, Mier W, Schad A, Kinscherf R, Askoxylakis V, Krämer S, et al. A new prostate carcinoma binding peptide (DUP-1) for tumor imaging and therapy. Clin Cancer Res 2005; 11:139-46; PMID:15671538.
144. Askoxylakis V, Mier W, Zitzmann S, Ehemann V, Zhang J, Krämer S, et al. Characterization and development of a peptide (p160) with affinity for neuroblastoma cells. J Nucl Med 2006; 47:981-8; PMID:16741308.
145. Zitzmann S, Krämer S, Mier W, Hebling U, Altmann A, Rother A, et al. Identification and evaluation of a new tumor cell-binding peptide, FROP-1. J Nucl Med 2007; 48:965-72; PMID:17504878; http://dx.doi.org/10.2967/jnumed.106. 036699.
146. Pazgier M, Liu M, Zou G, Yuan W, Li C, Li C, et al. Structural basis for high-affinity peptide inhibition of p53 interactions with MDM2 and MDMX. Proc Natl Acad Sci U S A 2009; 106:4665-70; PMID:19255450; http://dx.doi.org/10.1073/ pnas.0900947106.
147. Zurita AJ, Troncoso P, Cardó-Vila M, Logothetis CJ, Pasqualini R, Arap W. Combinatorial screenings in patients: the interleukin-11 receptor alpha as a candidate target in the progression of human prostate cancer. Cancer Res 2004; 64:435-9; PMID:14744752; http://dx.doi.org/10.1158/0008-5472.CAN-03-2675.
148. Pakkala M, Jylhäsalmi A, Wu P, Leinonen J, Stenman UH, Santa H, et al. Conformational and biochemical analysis of the cyclic peptides which modulate serine protease activity. J Pept Sci 2004; 10:439-47; PMID:15298179; http://dx.doi.org/10.1002/psc.557.
149. Kim Y, Lillo AM, Steiniger SC, Liu Y, Ballatore C, Anichini A, et al. Targeting heat shock proteins on cancer cells: selection, characterization, and cell-penetrating properties of a peptidic GRP78 ligand. Biochemistry 2006; 45:9434-44; PMID:16878978; http://dx.doi.org/10.1021/bi060264j.
150. Hetian L, Ping A, Shumei S, Xiaoying L, Luowen H, Jian W, et al. A novel peptide isolated from a phage display library inhibits tumor growth and metastasis by blocking the binding of vascular endothelial growth factor to its kinase domain receptor. J Biol Chem 2002; 277:43137-42; PMID:12183450; http://dx.doi.org/10.1074/jbc.M203103200.
151. Newton JR, Kelly KA, Mahmood U, Weissleder R, Deutscher SL. In vivo selection of phage for the optical imaging of PC-3 human prostate carcinoma in mice. Neoplasia 2006; 8:772-80; PMID:16984734; http://dx.doi.org/10.1593/neo. 06331.
152. Landon LA, Peletskaya EN, Glinsky VV, Karasseva N, Quinn TP, Deutscher SL. Combinatorial evolution of high-affinity peptides that bind to the Thomsen-Friedenreich carcinoma antigen. J Protein Chem 2003; 22:193-204; PMID:12760424; http://dx.doi.org/10.1023/A:1023483232397.
153. Thapa N, Kim S, So IS, Lee BH, Kwon IC, Choi K, et al. Discovery of a phosphatidylserine-recognizing peptide and its utility in molecular imaging of tumour apoptosis. J Cell Mol Med 2008; 12(5A):1649-60; PMID:18363834; http://dx.doi.org/10.1111/j.1582-4934.2008.00305.x.
154. Zang L, Shi L, Guo J, Pan Q, Wu W, Pan X, et al. Screening and identification of a peptide specifically targeted to NCI-H1299 from a phage display peptide library. Cancer Lett 2009; 281:64-70; PMID:19327883; http://dx.doi.org/10.1016/j.canlet.2009.02.021.
155. Koolpe M, Dail M, Pasquale EB. An ephrin mimetic peptide that selectively targets the EphA2 receptor. J Biol Chem 2002; 277:46974-9; PMID:12351647; http://dx.doi.org/10.1074/jbc.M208495200.
156. Howell RC, Revskaya E, Pazo V, Nosanchuk JD, Casadevall A, Dadachova E. Phage display library derived peptides that bind to human tumor melanin as potential vehicles for targeted radionuclide therapy of metastatic melanoma. Bioconjug Chem 2007; 18:1739-48; PMID:17907769; http://dx.doi.org/10.1021/ bc060330u.
157. Laakkonen P, Akerman ME, Biliran H, Yang M, Ferrer F, Karpanen T, et al. Antitumor activity of a homing peptide that targets tumor lymphatics and tumor cells. Proc Natl Acad Sci U S A 2004; 101:9381-6; PMID:15197262; http://dx.doi.org/10.1073/pnas.0403317101.
158. Simberg D, Duza T, Park JH, Essler M, Pilch J, Zhang L, et al. Biomimetic amplification of nanoparticle homing to tumors. Proc Natl Acad Sci U S A 2007; 104:932-6; PMID:17215365; http://dx.doi.org/10.1073/pnas.0610298104.
159. Fukuda MN, Ohyama C, Lowitz K, Matsuo O, Pasqualini R, Ruoslahti E, et al. A peptide mimic of E-selectin ligand inhibits sialyl Lewis X-dependent lung colonization of tumor cells. Cancer Res 2000; 60:450-6; PMID:10667600.
160. Yang J, Baskar S, Kwong KY, Kennedy MG, Wiestner A, Rader C. Therapeutic potential and challenges of targeting receptor tyrosine kinase ROR1 with monoclonal antibodies in B-cell malignancies. PLoS One 2011; 6:e21018; PMID:21698301; http://dx.doi.org/10.1371/journal.pone.0021018.
161. Fujiki T, Tsuji A, Matsumoto SE, Yamashita M, Teruya K, Shirahata S, et al. Generation of a human anti-tumor necrosis factor-α monoclonal antibody by in vitro immunization with a multiple antigen peptide. Biosci Biotechnol Biochem 2010; 74:1836-40; PMID:20834155; http://dx.doi.org/10.1271/bbb.100243.
162. Cyranka-Czaja A, Wulhfard S, Neri D, Otlewski J. Selection and characterization of human antibody fragments specific for psoriasin - a cancer associated protein. Biochem Biophys Res Commun 2012; 419:250-5; PMID:22342672; http://dx.doi.org/10.1016/j.bbrc.2012.02.003.
163. Lin J, Huo R, Wang L, Zhou Z, Sun Y, Shen B, et al. A novel anti-Cyr61 antibody inhibits breast cancer growth and metastasis in vivo. Cancer Immunol Immunother 2012; 61:677-87; PMID:22048717; http://dx.doi.org/10.1007/s00262-011- 1135-y.
164. Brack SS, Silacci M, Birchler M, Neri D. Tumor-targeting properties of novel antibodies specific to the large isoform of tenascin-C. Clin Cancer Res 2006; 12:3200-8; PMID:16707621; http://dx.doi.org/10.1158/1078-0432.CCR-05-2804.
165. nd, et al. Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas. J Clin Oncol 2002; 20:1389-97; PMID:11870184; http://dx.doi.org/10.1200/JCO.20.5.1389.
166. Rizzieri DA, Akabani G, Zalutsky MR, Coleman RE, Metzler SD, Bowsher JE, et al. Phase 1 trial study of 131I-labeled chimeric 81C6 monoclonal antibody for the treatment of patients with non-Hodgkin lymphoma. Blood 2004; 104:642-8; PMID:15100153; http://dx.doi.org/10.1182/blood-2003-12-4264.
167. Villa A, Trachsel E, Kaspar M, Schliemann C, Sommavilla R, Rybak JN, et al. A high-affinity human monoclonal antibody specific to the alternatively spliced EDA domain of fibronectin efficiently targets tumor neo-vasculature in vivo. Int J Cancer 2008; 122:2405-13; PMID:18271006; http://dx.doi.org/10.1002/ ijc.23408.